Dyax Corp. Launches Hereditary Angioedema (HAE) Attack Tracker™, a Free iPhone Application for HAE Patients

Dyax Corp. (NASDAQ: DYAX) today announced the launch of a free smartphone application for the iPhone – HAE Attack Tracker™. This application allows HAE patients to keep detailed records of their disease related information, including emergency and physician contacts as well as individual attack data.

“Recording and tracking triggers and symptoms of HAE attacks can be an important tool in managing this disease,” said Chief Medical Officer Dr. Burt Adelman of Dyax. “Understanding the frequency and severity of these attacks can be of real value to both patients and their treating physicians.”

Dyax is fully committed to delivering outstanding services and support to meet the needs of HAE patients. Developed by a team of patient education specialists at Dyax, along with input from HAE patients, the HAE Attack Tracker is the first and only iPhone application designed specifically for HAE patients.

“Dyax is strongly committed to the HAE community and bringing awareness to this rare and often misdiagnosed disease. We continue to find new ways to bring resources to this community taking into account patient and physician feedback,” said Gustav Christensen, President and Chief Executive Officer of Dyax. “The HAE Attack Tracker iPhone application provides a reference for patients and physicians, allowing them to monitor their HAE attacks and track a number of metrics that could help in the management of their condition.“

The app is a personal mobile diary to track HAE attack history, with the following key features:

• Records important information related to each attack such as date, anatomical location, possible triggers, warning signs, duration and treatment
• Allows user to write personal notes and attach pictures related to individual attacks
• Allows user to share HAE attack information with their treating physician via email
• Has options to store and compile data regarding attacks, including information on frequency, severity, most common triggers and attack locations, over a specified time period

HAE patients with an iPhone can download the HAE Attack Tracker application through the iTunes Store. Future versions for other smartphone platforms will be released later in 2012.

About HAE
Hereditary angioedema (HAE) is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood. HAE is estimated to affect 1 in 10,000 to 1 in 50,000 individuals. Learn more at www.HAEHope.com.

About Dyax
Dyax is a fully integrated biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s lead product, ecallantide, has been approved under the brand name KALBITOR in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

Dyax is commercializing KALBITOR in the United States independently, and establishing strategic collaborations to develop and commercialize ecallantide for the treatment of HAE in key regions worldwide. Currently, Dyax has collaboration agreements for regions including Europe, Japan, Russia, the Middle East, North Africa, Australia, New Zealand, Latin America (excluding Mexico) and the Caribbean. Dyax is also exploring other potential indications for ecallantide, either alone or through collaborations, including drug-induced angioedema.

Ecallantide and other compounds in Dyax’s pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through its Licensing and Funded Research Program (LFRP). Collectively, these agreements associated with the LFRP generate significant revenue for Dyax in the form of license fees, milestone payments and/or royalties. The success of the LFRP is illustrated by the program’s advanced licensee pipeline that includes 18 candidates in clinical development. Of those candidates, four are in Phase 3 clinical trials, four are in Phase 2 and ten are in Phase 1.

Dyax is headquartered in Burlington, Massachusetts. For online information about Dyax Corp., please visit www.dyax.com.